• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2014 Fiscal Year Final Research Report

The suppressant effect of everolimus against HCC after liver transplantation

Research Project

  • PDF
Project/Area Number 24791410
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Digestive surgery
Research InstitutionKyoto University

Principal Investigator

TAKASHI Ito  京都大学, 医学(系)研究科(研究院), 非常勤講師 (10378656)

Research Collaborator HAMAGUCHI Yuhei  
KAIDO Toshimi  
UEMOTO Shinji  
Project Period (FY) 2012-04-01 – 2015-03-31
Keywords肝臓移植 / 肝臓癌 / エベロリムス
Outline of Final Research Achievements

In this study, we analyzed the liver transplantation recipient of hepatocellular carcinoma (HCC). We performed 24 cases between April 2012 and March 2015. One case was died due to sepsis after transplantation. Four cases were beyond Milan criteria, and the remnant case was in Milan criteria. All patients were not occurred recurrence of HCC for 2years. Three cases was received Everolimus as immunosuppressant after liver transplantation. These cases have no recurrence of HCC, and was beyond Milan criteria. Tumor makers and immunosuppress cells such as CD4/8/25 cells was not significantly difference between evelorimus group and other groups.
We could establish the new HCC recurrence model in SD rats using N1S1 hepatoma cells by adding IR injury and partial hepatectomy in our basic study. This new model can be easily and universally developed, so it could be a good model to investigate the mechanisms of HCC recurrence and to evaluate the effects of new therapeutic agents for HCC.

Free Research Field

肝臓移植、肝胆膵外科

URL: 

Published: 2016-06-03  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi